Cartesian Therapeutics files financials for acquired Old Cartesian and pro forma

Cartesian Therapeutics, Inc.

Old Cartesian net loss $6.5M in 2022, vs $3.6M in 2021; grant revenue $1.4M in 2022.
Old Cartesian cash $12.0M at Dec 31, 2022; accumulated deficit $26.1M.
Unaudited pro forma financials reflect combined entity post-merger closed Nov 13, 2023.

item 9.01

Cartesian Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-24-003407

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.